HK1018742A1 - Preparation containing a combination of 5-methylisoxazole-4-carboxyclic acid-(4-triflouromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide - Google Patents

Preparation containing a combination of 5-methylisoxazole-4-carboxyclic acid-(4-triflouromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide

Info

Publication number
HK1018742A1
HK1018742A1 HK99103705A HK99103705A HK1018742A1 HK 1018742 A1 HK1018742 A1 HK 1018742A1 HK 99103705 A HK99103705 A HK 99103705A HK 99103705 A HK99103705 A HK 99103705A HK 1018742 A1 HK1018742 A1 HK 1018742A1
Authority
HK
Hong Kong
Prior art keywords
trifluoromethylphenyl
cyano
triflouromethyl
methylisoxazole
anilide
Prior art date
Application number
HK99103705A
Other languages
English (en)
Inventor
Robert Bartlett
Original Assignee
Aventis Pharm Deutschland And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7788856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1018742(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharm Deutschland And filed Critical Aventis Pharm Deutschland And
Publication of HK1018742A1 publication Critical patent/HK1018742A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK99103705A 1996-03-20 1999-08-27 Preparation containing a combination of 5-methylisoxazole-4-carboxyclic acid-(4-triflouromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide HK1018742A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19610955A DE19610955A1 (de) 1996-03-20 1996-03-20 Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
PCT/EP1997/001167 WO1997034600A1 (de) 1996-03-20 1997-03-07 Kombinationspräparat, enthaltend 5-methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid und n-(4-trifluormethylphenyl)-2-cyan-3-hydroxycrotonsäureamid

Publications (1)

Publication Number Publication Date
HK1018742A1 true HK1018742A1 (en) 2000-01-07

Family

ID=7788856

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99103705A HK1018742A1 (en) 1996-03-20 1999-08-27 Preparation containing a combination of 5-methylisoxazole-4-carboxyclic acid-(4-triflouromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide

Country Status (23)

Country Link
US (1) US7071222B2 (xx)
EP (1) EP0896537B1 (xx)
JP (1) JP4206131B2 (xx)
KR (1) KR100464693B1 (xx)
CN (1) CN1141095C (xx)
AT (1) ATE183393T1 (xx)
AU (1) AU705692B2 (xx)
BG (1) BG64189B1 (xx)
BR (1) BR9708108A (xx)
CY (1) CY2209B1 (xx)
CZ (1) CZ289446B6 (xx)
DE (2) DE19610955A1 (xx)
ES (1) ES2137055T3 (xx)
GR (1) GR3031637T3 (xx)
HK (1) HK1018742A1 (xx)
HU (1) HU226677B1 (xx)
NO (1) NO315595B1 (xx)
NZ (1) NZ331933A (xx)
PL (1) PL188052B1 (xx)
RU (1) RU2198655C2 (xx)
TR (1) TR199801862T2 (xx)
UA (1) UA46103C2 (xx)
WO (1) WO1997034600A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE19960443C2 (de) 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
CA2441088A1 (en) * 2001-03-13 2002-09-19 Protagen Ag 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
DE10112925A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren, Aminosäureanalogen zur Modulation von Transaminasen und/oder der Assoziation p36/Malat Dehydrogenase
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
ATE450498T1 (de) 2002-12-23 2009-12-15 4Sc Ag Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
UA108760C2 (uk) 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US20210017125A1 (en) 2018-03-16 2021-01-21 Immunic Ag Novel calcium salt polymorphs as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents
WO2021214033A1 (en) 2020-04-21 2021-10-28 Immunic Ag Vidofludimus for use in the treatment or prevention of viral diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
DK0527736T3 (da) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Also Published As

Publication number Publication date
NO984343L (no) 1998-09-18
CY2209B1 (en) 2002-11-08
CZ298598A3 (cs) 1998-12-16
AU705692B2 (en) 1999-05-27
CN1141095C (zh) 2004-03-10
EP0896537A1 (de) 1999-02-17
DE19610955A1 (de) 1997-09-25
RU2198655C2 (ru) 2003-02-20
TR199801862T2 (xx) 1998-12-21
BG64189B1 (bg) 2004-04-30
PL188052B1 (pl) 2004-12-31
NO984343D0 (no) 1998-09-18
US7071222B2 (en) 2006-07-04
WO1997034600A1 (de) 1997-09-25
CN1213302A (zh) 1999-04-07
ATE183393T1 (de) 1999-09-15
HU226677B1 (en) 2009-06-29
EP0896537B1 (de) 1999-08-18
BG102697A (en) 1999-09-30
HUP9902130A3 (en) 2001-01-29
JP4206131B2 (ja) 2009-01-07
DE59700356D1 (en) 1999-09-23
ES2137055T3 (es) 1999-12-01
KR100464693B1 (ko) 2005-04-19
NZ331933A (en) 2000-06-23
PL328998A1 (en) 1999-03-01
US20020006945A1 (en) 2002-01-17
GR3031637T3 (en) 2000-02-29
AU1926197A (en) 1997-10-10
BR9708108A (pt) 1999-07-27
HUP9902130A2 (hu) 1999-11-29
KR20000064757A (ko) 2000-11-06
CZ289446B6 (cs) 2002-01-16
UA46103C2 (uk) 2002-05-15
NO315595B1 (no) 2003-09-29
JP2000510440A (ja) 2000-08-15

Similar Documents

Publication Publication Date Title
HK1018742A1 (en) Preparation containing a combination of 5-methylisoxazole-4-carboxyclic acid-(4-triflouromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
PL323627A1 (en) Alternation of amino acid composition of seeds
IL112495A0 (en) Phenylacetic acid derivatives, their preparation and compositions containing them
IL94348A0 (en) Fungicidal agents,comprising substituted amino acid amide derivatives,certain such novel derivatives and their preparation
EP2270046A3 (en) Methods and compositions for the treatment of hemolysis-associated diseases
CA2255652A1 (en) Isobutylgaba and its derivatives for the treatment of pain
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
US5656608B1 (en) Amino acid compositions and methods of treatment using same
MY115211A (en) Novel amino acid derivatives, their preparation and use
AU4018897A (en) Novel 3,4-diaryloxazolone derivatives, methods of preparation and therapeutic uses thereof
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
IT1272924B (it) Procedimento per la preparazione di composti ciclopentadienilici e composti cosi' ottenibili
BG102814A (en) New derivatives of carboxylic acid, their preparation and application
AU2467395A (en) Novel ophthalmologic uses of protein c
ZA908724B (en) Substituted amino acid amide derivatives,their preparation and use
GB9515279D0 (en) Improved therapeutic agents
IT1241631B (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
CA2100720A1 (en) Medicinal composition comprising tcf-ii
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
EP0382180A3 (en) Derivatives of thiazolidine-4-carboxylic acid, its preparation and pharmaceutical compositions containing it
JPS6416755A (en) Manufacture of n-(3',4'-dimethoxycinnamoyl)-aniline derivative
AU4448497A (en) Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
CA2249348A1 (en) Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
WO2000027881A3 (de) Menschliche interleukin -10 mutantenproteine
GB9710636D0 (en) Novel mixture

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170306